MINI REVIEW article

Front. Oncol., 17 June 2024

Sec. Cancer Molecular Targets and Therapeutics

Volume 14 - 2024 | https://doi.org/10.3389/fonc.2024.1408051

Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature

  • 1. Department of Oncology, Lianyungang Clinical College of Nanjing Medical University, Lianyungang, China

  • 2. Department of Oncology, The Affiliated Lianyungang Hospital of Xuzhou Medical University, Lianyungang, China

Abstract

B7-H3 (CD276), an immune checkpoint molecule, is overexpressed in various types of cancer and their tumor vasculature, demonstrating significant associations with adverse clinical outcomes. In addition to its well-known immune functions, B7-H3 exhibits dual co-stimulatory/co-inhibitory roles in normal physiology and the tumor microenvironment. The non-immune functions of B7-H3 in tumor cells and the tumor vasculature, including promoting tumor cell anti-apoptosis, proliferation, invasion, migration, drug resistance, radioresistance, as well as affecting cellular metabolism and angiogenesis, have increasingly gained attention from researchers. Particularly, the co-expression of B7-H3 in both tumor cells and tumor endothelial cells highlights the higher potential and clinical utility of therapeutic strategies targeting B7-H3. This review aims to summarize the recent advances in understanding the non-immune functions of B7-H3 in tumors and provide insights into therapeutic approaches targeting B7-H3, focusing on its co-expression in tumor cells and endothelial cells. The aim is to establish a theoretical foundation and practical reference for the development and optimization of B7-H3-targeted therapies.

1 Introduction

CD276, also known as B7 homolog 3 (B7-H3), is a type I transmembrane protein consisting of 316 amino acids. It is encoded by the gene located on chromosome 9 in mice and the human 15q24 region. The primary structure of B7-H3 includes an extracellular Ig-like domain, a transmembrane region, and a short cytoplasmic tail (1). Based on the number of extracellular Ig-like domains, membrane-bound B7-H3 can be classified into two isoforms: 2IgB7-H3 and 4IgB7-H3. The former contains one IgV (variable) and one IgC (constant) domain, while the latter possesses tandem IgV and IgC domains due to exon duplication (2).

B7-H3 is a cell surface tumor endothelial marker with up toĀ 30% amino acid homology to other members of the B7 family. ItĀ is also expressed in tumor-associated endothelial cells and is often associated with advanced tumor staging (3). B7-H3 has been shown to differentiate pathological and physiological angiogenesis in both mice and humans (4). The high expression of B7-H3 protein is observed in various human cancers such as lung, breast, colon, endometrial, renal, and ovarian cancer tumor vasculature, while it is not expressed in normal ovarian vasculature (5).

Although initially characterized as a T-cell co-stimulatory protein, current research describes B7-H3 as a T-cell inhibitory molecule that promotes tumor invasion and proliferation. It mediates immune escape primarily by inhibiting T-cell infiltration and promoting CD8+ T-cell exhaustion, suggesting that B7-H3 may serve as an important immune target in cancer therapy (6). However, B7-H3 also functions as an independent protein outside of the immune system, participating in non-immune responses in tumors. It plays a crucial role in tumor cell anti-apoptosis, proliferation, invasion, migration, drug resistance, radioresistance, metabolism, and angiogenesis (7). The exact mechanisms through which B7-H3 promotes tumor development independently of the immune system are not fully understood. Nevertheless, extensive research suggests that B7-H3 may exert its effects upstream of signaling pathways, indicating that targeting these pathways could provide new approaches for cancer treatment (3). The non-immune functions of B7H3 promoting tumor progression are summarized in FigureĀ 1.

FigureĀ 1

2 B7-H3 in the non-immune functions of tumors

2.1 Anti-apoptosis

Apoptosis is a genetically regulated, orderly process of cell death primarily responsible for eliminating aged or abnormal cells. Resistance to apoptosis has been widely recognized as a crucial hallmark of malignant tumors (8). B7-H3 promotes tumor development by suppressing apoptosis in tumor cells (9). In a multi-omic analysis and single-cell sequencing study, Zhou etĀ al. found a significant increase in B7-H3 levels during the cellular senescence process in tumor cells, suggesting a critical role of B7-H3 in preventing tumor cell senescence (10). On the other hand, the role of B7-H3 in tumor growth has also garnered attention. Early studies on breast cancer cells demonstrated that silencing B7-H3 expression in the MCF-7 cell line led to an upregulation of vascular endothelial growth factor (VEGF) at both mRNA and protein levels, indicating that B7-H3 may inhibit tumor growth by suppressing VEGF expression (11). However, subsequent research revealed that the expression of B7-H3 actually facilitates tumor growth in other breast cancer cell lines, suggesting a complex and potentially contradictory role of B7-H3 in the pathogenesis of breast cancer (12). These findings indicate that B7-H3 may play a multifaceted role in the development of tumors, with specific effects likely dependent on the tumor type, underlying mechanisms, and biological context. Nonetheless, the majority of current research supports the view that B7-H3 promotes tumor growth through its anti-apoptotic effects. The summary of signaling pathways mediating the anti-apoptotic effects of B7-H3 is presented in TableĀ 1.

TableĀ 1

FunctionCancer TypeMechanismReferences
Anti-apoptosisColorectal CancerUpregulates the Jak2-Stat3 signaling pathway to enhance the expression of downstream anti-apoptotic proteins Bcl-2 and Bcl-xl, thereby strengthening tumor cell resistance against apoptosis(13)
Colorectal CancerSuppresses cellular senescence in colorectal cancer cells through the AKT/TM4SF1/SIRT1 pathway(14)
Gastric CancerInhibits tumor cell apoptosis by regulating the PI3K/AKT signaling pathway mediated by fibronectin(8)
Cervical Intraepithelial Neoplasia and Cervical CancerInduces tumor cell apoptosis by modulating the E7/Rb pathway, affecting cell cycle and apoptosis(15)
Proliferation, Invasion, MigrationBreast CancerRegulates MEK to induce tumor stem cell proliferation(16)
Head and Neck Squamous Cell CarcinomaActivates AP-1 to promote cancer stem cell invasion and metastasis(17)
Ovarian CancerAffects tumor cell invasion, migration, and proliferation through the Jak2/Stat3 pathway(18)
Gastric CancerSilencing B7-H3 downregulates CXCR4 related to metastasis and inhibits phosphorylation of AKT, ERK, and Jak2/Stat3, suppressing tumor cell migration and invasion(19)
GlioblastomaEnhances tumor cell proliferation and invasion through the activation of Jak2/Stat3/Slug signaling pathway. Induces EMT process by downregulating E-cadherin and upregulating MMP-2/9 expression, leading to increased invasion of glioblastoma cells(20)
Pancreatic Ductal AdenocarcinomaBRD4/B7-H3/TLR4 axis promotes tumor cell proliferation, invasion, and metastasis(21)
Liver CancerTargets epithelial-mesenchymal transition (EMT) through the Jak2/Stat3/Slug signaling pathway while promoting the expression of MMP-2 and MMP-9 to enhance tumor metastasis and invasion(22)
Non-Small Cell Lung CancerUpregulates SIRT1 expression through the PI3K/AKT pathway, activating EMT and inducing migration(23)
MelanomaKnockdown of B7-H3 reduces MMP-2 mRNA levels and proMMP-2 protein expression, as well as decreases phosphorylation of Stat3 and secretion of IL-8, leading to decreased metastatic capability(24)
Breast CancerAccelerates lung metastasis by activating the Raf/MEK/ERK signaling pathway(25)
Clear Cell Renal Cell CarcinomaPromotes tumor cell invasion and metastasis in a fibronectin-dependent manner, accompanied by upregulation of phosphorylated proteins in the PI3K/AKT and p38/ERK MAPK signaling pathways(26)
Drug ResistanceBreast CancerPartially induces paclitaxel resistance by interfering with the Jak2/Stat3 pathway(27)
Pancreatic CancerInduces gemcitabine resistance through downregulation of survivin expression(28)
MelanomaMediates dacarbazine and cisplatin resistance via DUSP10-mediated p38 MAPK inactivation(29)
Colorectal CancerUpregulates expression of X-ray repair cross-complementing protein 1 (XRCC1) through the PI3K-AKT pathway, promoting oxaliplatin resistance(30)
Colorectal CancerReduces G2/M phase arrest in a CDC25A-dependent manner, enhancing resistance to oxaliplatin or 5-fluorouracil(31)
Ovarian CancerInduces activation of the PI3K/AKT signaling pathway, leading to treatment resistance(32)
MetabolismEsophageal Squamous Cell CarcinomaInduces phosphorylation of PKM2 through the Stat3 signaling pathway, promoting glucose metabolism(33)
Breast CancerRegulates glucose metabolism by inhibiting Nrf2 and its target genes, increasing protein levels of HIF1α, LDHA, and PDK1(34)
Colorectal CancerRegulates glucose metabolism by inhibiting Nrf2 and its target genes, increasing protein levels of HIF1α, LDHA, and PDK1(34)
Oral Squamous Cell CarcinomaEnhances glycolysis by upregulating Glut1 and PFKFB3 through the PI3K/AKT/mTOR/HIF-1α pathway(35)
Colorectal CancerRegulates glucose metabolism by controlling the expression of HK2(36)
NeuroblastomaIncreases glucose uptake and lactate production by regulating the Stat3/c-Met pathway and increasing PFKFB3 expression(37)
AngiogenesisNeuroblastomaInduces angiogenesis through MMP-2 and MMP-9(38)
Colorectal CancerUpregulates VEGFA expression and promotes angiogenesis by activating the NF-ĪŗB pathway(39)
Colorectal CancerPromotes tumor angiogenesis and metastasis through activation of the AKT1/mTOR/VEGFA signaling pathway(40)
Breast CancerInhibits tumor growth by suppressing VEGF expression(11)
Clear Cell Renal Cell CarcinomaPromotes angiogenesis through the Tie-2 pathway(41)
Angiogenic MimicryNSCLCPromotes VM formation in NSCLC cells through the PI3K/AKT signaling pathway(42)
Hepatocellular CarcinomaPromotes VM formation by activating the PI3K/AKT/MMPs pathway and upregulating the expression of MMP2, MMP14, VE-cadherin, and vimentin during EMT process(43)

Signaling Pathways Mediating the Diverse Functions of B7-H3.

B7-H3, B7 homolog 3; Jak2, Janus kinase 2; TM4SF1, transmembraneāˆ’4 L6 family member 1; SIRT1, sirtuin 1;Nrf2 and its target genes, increasing protein levels of HIF1α, hypoxiaāˆ’inducible factorāˆ’1α; LDHA, lactate dehydrogenase A; PDK1, phosphoinositide-dependent protein kinase-1; PFKFB3, 6-Phosphofructo 2-kinase/fructose 2, 6-bisphosphatase 3;VM, vasculogenic mimicry.

2.2 Proliferation, invasion, migration

Recent studies have revealed the significant role of B7-H3 in promoting cancer cell proliferation, migration, and invasion (21, 35, 44, 45). In various cancers, including oral cancer, hepatocellular carcinoma, colorectal cancer, lung adenocarcinoma, hematologic malignancies, and gynecologic tumors, B7-H3 has been found to promote cancer cell proliferation by regulating different signaling pathways (46). B7-H3 can also enhance cancer cell migration by modulating the expression of E-cadherin, increasing their migratory capacity (20). Additionally, B7-H3 can augment cancer cell invasion into surrounding tissues by regulating the activity of matrix metalloproteinases (MMPs) (22). These findings provide us with new insights and suggest that targeting B7-H3 and its associated signaling pathways could be an effective strategy for the treatment of these cancers. The summary of signaling pathways mediating the proliferation, invasion, and migration effects of B7-H3 is presented in TableĀ 1.

2.3 Drug resistance

Drug resistance is a reflection of tumor evolution and is a major cause of cancer recurrence and patient mortality (47). Studies have shown that overexpression of B7-H3 often leads to drug resistance in cancer cells. Different mechanisms of resistance exist in different tumor cells. For example, the high expression of the B7-H3 immune checkpoint protein in neuroblastoma is involved in carcinogenic signaling, tumor cell plasticity, and theĀ development of drug resistance (48). However, inhibiting the expression of B7-H3 or blocking its associated signaling pathways can reverse this resistance. One approach is to use a combination of paclitaxel and MEK inhibitors to block the B7-H3 signal, which has been demonstrated to effectively reverse chemotherapy resistance (16). Another approach is to use the specific inhibitor LY294002 to block the PI3K signaling pathway, which can also effectively inhibit this resistance (49). Another study found that bromodomain and extra-terminal domain inhibitors could be used to reduce the levels of B7-H3 protein and mRNA in pancreatic cancer cells, providing a new therapeutic strategy to overcome immune and chemotherapy resistance in pancreatic cancer (21). In related studies on traditional Chinese medicine, researchers found that artemisinin-mediated inhibition of B7-H3 may help enhance neuroblastoma cell sensitivity to doxorubicin (50). Additionally, Astragaloside IV enhanced the chemosensitivity to cisplatin by inhibiting B7-H3, suggesting that a combination therapy using Astragaloside IV and a B7-H3 inhibitor may be a potential treatment method for lung cancer patients (51). The summary of signaling pathways mediating the drug resistance effects of B7-H3 is presented in TableĀ 1.

2.4 Radiation resistance

Radiation therapy is a common treatment modality for solidĀ tumors; however, radiation resistance is a major factor contributing to treatment failure in cancer (52). A study by Ma etĀ al. reported an interesting phenomenon: after X-ray irradiation, the expression of B7-H3 was upregulated in colorectal cancer cells, and this upregulation depended on the upregulation of KIF15 via the NF-ĪŗB signaling pathway. Further research revealed that B7-H3/KIF15, through activation of the ERK1/2 signaling pathway, promoted radiation resistance in colorectal cancer (31). Additionally, Zhou etĀ al. found that B7-H3 increased the radiation resistance of gastric cancer cells by regulating baseline levels of cellular autophagy. In cells with high B7-H3 expression, increasing the baseline level of cellular autophagy using rapamycin enhanced their sensitivity to radiation (32). These studies all point to the important role of B7-H3 in regulating tumor cell resistance to radiation therapy. Therefore, finding effective ways to inhibit or modulate the expression and function of B7-H3 may provide new strategies to improve the effectiveness of radiation therapy.

2.5 Metabolism

The Warburg effect is one of the characteristic features of tumor cell metabolism, where cancer cells tend to produce energy through glycolysis even in the presence of abundant oxygen, which is significantly different from the metabolic mechanism of normal cells (53). Research by Lim etĀ al. found that B7-H3 plays an important role in the metabolic reprogramming of cancer cells. In cells expressing B7-H3, glucose uptake and lactate production are increased (34). On the other hand, there is an interaction between the glycolytic enzyme ENO1 and B7-H3. Downregulation of B7-H3 in cervical cancer HeLa cells leads to decreased levels of ATP, lactate, c-Myc, and lactate dehydrogenase A (54). Furthermore, overexpression of B7-H3 effectively increases glucose consumption and lactate production rate, while knockout of B7-H3 has the opposite effect. Liu etĀ al. demonstrated that using the anti-B7-H3 antibody 8H9 can shift cellular metabolism from glycolysis to oxidative phosphorylation, and they suggested that anti-B7-H3 blockade may alter tumor glucose metabolism through reactive oxygen species-mediated pathways by measuring cellular ROS levels in A549 cells treated with the anti-B7-H3 antibody using fluorescence probes (55). In addition to changes in glucose metabolism, cancer cells often possess altered fatty acid metabolism properties. In glioma cells, genetic risk features associated with fatty acid catabolism are significantly correlated with the immune checkpoint molecule B7-H3 (56). These research findings further emphasize the important role of B7-H3 in the metabolic regulation of cancer cells and may provide new therapeutic strategies for targeting this process. The summary of signaling pathways mediating the metabolism effects of B7-H3 is presented in TableĀ 1.

3 The role of B7-H3 in tumor vasculature and clinical treatment

3.1 The role of B7-H3 in tumor vasculature

In cancer development, angiogenesis plays a crucial role by providing oxygen and nutrients to tumors while allowing their spread to other parts of the body. Thus, inhibiting or reducing the blood supply in the tumor microenvironment to restrict tumor angiogenesis has become a key strategy against various solid tumors (57). B7-H3 is a highly expressed protein in many types of cancer, including lung, breast, colorectal, endometrial, renal, ovarian, hepatocellular carcinoma, and melanoma. However, this protein is not expressed in normal vascular tissues (4, 5). Furthermore, in hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, and melanoma, the expression rate of B7-H3 in the tumor vasculature reaches 86% to 98% (58). In ovarian cancer, although the expression rate of B7-H3 is only 44%, it is undetectable in normal ovarian vascular tissues (5).

Under normal physiological conditions, the process of angiogenesis is strictly regulated by factors that promote and inhibit angiogenesis to maintain a stable internal environment and prevent uncontrolled blood vessel growth. However, B7-H3 protein can disrupt this balance by enhancing the activity of several pro-angiogenic factors, favoring tumor development (9). It mainly activates multiple signaling pathways, such as MMP-2, MMP-9, NF-ĪŗB, AKT1/mTOR/VEGFA, and Tie-2, thus promoting tumor angiogenesis and further facilitating tumor growth and spread (38–41). By inhibiting key molecules in these signaling pathways, we can effectively inhibit angiogenesis. For example, in neuroblastoma, overexpression of miR-29 can activate the JAK/STAT1 signaling pathway, weakening the regulatory effect of MYC-B7-H3 and inhibiting tumor angiogenesis (38). Additionally, Wang etĀ al. found that recombinant VEGFA can eliminate the inhibitory effect of shB7-H3 on human umbilical vein endothelial cell angiogenesis in conditioned medium from colorectal cancer cells. Furthermore, siRNA against VEGFA or neutralizing antibodies against VEGFA can reverse the effects of B7-H3 in overexpressed colorectal cancer cell-conditioned medium on human umbilical vein endothelial cell angiogenesis (39). These studies further elucidate the potential role of B7-H3 in tumor angiogenesis and may serve as a crucial target for future anti-angiogenic therapies.

Moreover, B7-H3 also plays an important role in vasculogenic mimicry (VM). VM is an alternative microcirculation pattern independent of angiogenesis, where cancer cells form microvascular-like channels to provide nutrients and oxygen to tumors (59). Recent studies have found that B7-H3 expressed in tumors promotes VM formation in non-small cell lung cancer cells through the PI3K/AKT signaling pathway without affecting normal angiogenesis, providing a new strategy for future anticancer therapies (42). The summary of signaling pathways mediating B7-H3-induced tumor angiogenesis is presented in TableĀ 1.

3.2 Clinical treatment

In numerous types of tumors, the widespread overexpression of B7-H3 on cancer cells and tumor-associated blood vessels makes it a potential ideal dual-target for therapy. CD276-ADC, utilizing pyrrolobenzodiazepine as a linker, demonstrates significant cytotoxicity against cancer cells while also exhibiting remarkable destructive effects on the tumor vascular system. This therapy shows great potential in eradicating large existing tumors and metastatic lesions, with the possibility of significantly improving long-term overall survival rates for patients (5). To target the overexpression of B7-H3 in tumor cells and tumor vasculature, along with its limited expression in normal tissue vasculature, researchers have employed an innovative strategy by conjugating the Fab fragment of anti-CD276 antibody with the photosensitizer IRDye700 to form a novel CD276-targeted agent. The findings show that combining photodynamic therapy using this agent with inhibition strategies targeting the PD-L1/PD-1 axis can induce strong local and systemic anti-tumor responses, effectively eliminating primary and metastatic tumors (60). Chen etĀ al. reported the development of pH-responsive drug release using B7H3-targeted doxorubicin-conjugated gold nano-cages (B7H3/Dox@GNCs), which represents a selective, precise, and synergistic chemotherapy-photothermal therapy for NSCLC, capable of simultaneously destroying B7H3-positive tumor cells, tumor-associated vasculature, and cancer-associated fibroblasts (61). The expression of B7-H3 in the tumor vasculature can also be utilized to significantly improve the diagnostic accuracy of breast cancer, which is undoubtedly an important discovery (62).

Furthermore, as a promising immunotherapy target, B7-H3 has been applied in combination treatment strategies. When used as a key element in T cell co-stimulation and anti-angiogenesis therapy for hepatocellular carcinoma, the effect of B7-H3 is significantly superior to using these treatments alone. Injecting plasmids expressing B7-H3 into subcutaneous tumors in mice resulted in complete eradication of these tumors within 24 hours, which was not achieved when using angiostatin or B7-H3 treatment alone (63). This process revealed the ability of angiostatin gene transfer to inhibit tumor angiogenesis and enhance NK cell infiltration, as well as the critical role of B7-H3 in activating CD8+ tumor infiltration, increasing circulating IFN-c levels, and even completely regressing distant tumor nodules (63). However, although B7-H3 plays an important role in the aforementioned combination treatment strategies, its primary role in the broader field of immunotherapy is still as an immune checkpoint inhibitor. For example, in the treatment of triple-negative breast cancer, Cheng etĀ al. found that blocking B7-H3 with anti-B7-H3 antibodies improved the abnormal state of the tumor vascular system, thereby enhancing the effects of chemotherapy and PD-1 treatment (64). These research findings further emphasize that B7-H3 can serve as an important therapeutic target in anticancer treatment strategies, whether used alone or in combination with other treatment modalities. More clinical trials targeting B7-H3 for cancer treatment are listed in TableĀ 2.

TableĀ 2

Intervention typeInterventionTrial numberPhaseCancer type
ADCCMGA271NCT01918930IMelanoma
NCT02982941INeuroblastoma
Rhabdomyosarcoma
Osteosarcoma
NCT01391143IProstate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer, Head and Neck Cancer, Bladder Cancer, Non-small Cell Lung Cancer
NCT0298294INeuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Wilms Tumor, Desmoplastic Small Round Cell Tumor
NCT02923180IIProstate Cancer
DS-5573aNCT02192567IAdvanced Solid Malignant Tumors
ADCMGC018NCT03729596I/IIAdvanced Solid Malignant Tumors
I-DXdNCT05280470IIExtensive-stage Small-cell Lung Cancer
NCT06330064IIRecurrent or Metastatic Solid Tumors
NCT06203210IIISmall Cell Lung Cancer
NCT06362252Ib/IIExtensive Stage-small Cell Lung Cancer
HS-20093NCT06112704IIAdvanced Solid Tumors
NCT06332170IAdvanced Solid Tumors
NCT05830123IIOsteosarcoma
Sarcoma
NCT05276609IAdvanced Solid Tumors
NCT06001255IIMetastasis Castration Resistant Prostate Cancer(mCRPC)
NCT06007729IIHead and Neck Squamous Cell Carcinoma
BAT8009NCT05405621ILocally Advanced/Metastatic Solid Tumours
DS-7300aNCT04145622I/IIAdvanced Solid Tumor
Malignant Solid Tumor
B7-H3 X CD3 BiAbMGD009NCT02628535I13 Types of Tumors
CAR-TB7-H3-CAR T cellsNCT04897321I15 Types of Tumors
NCT05835687I7 Types of Central Nervous System Tumors
NCT04185038I10 Types of Central Nervous System Tumors
NCT04670068IEpithelial Ovarian Cancer
NCT05474378IBrain and Nervous System
NCT05366179IGlioblastoma Multiforme
NCT05190185IMalignant Melanoma, Lung Cancer, or Colorectal Cancer
NCT04385173IRecurrent Glioblastoma
Refractory Glioblastoma
NCT04077866I/IIRecurrent Glioblastoma
Refractory Glioblastoma
NCT05241392IGlioblastoma
NCT04864821Early Phase 1Osteosarcoma, Neuroblastoma, Gastric Cancer, Lung Cancer
NCT05143151I/IIAdvanced Pancreatic Carcinoma
NCT05562024IB7-H3-positive Relapsed/Refractory Neuroblastoma
NCT06221553Early Phase 1DIPG Brain Tumor
Diffuse Intrinsic Pontine Glioma
second generation 4–1BBζ B7H3-EGFRt-DHFRNCT04483778I16 Types of Pediatric Solid Tumors
SC- CAR 4BRAINNCT05768880IMalignant Central Nervous System Neoplasm
B7-H3 UCAR-T cellNCT05752877Advanced Glioma
Complication of Chimeric Antigen Receptor (CAR-T) Cell Therap
KT095 CAR-T cellNCT05515185Early Phase 1Advanced Solid Tumor
B7-H3 and 11 other engineered CAR-TNCT04842812ILiver CancerLung CancerBreast CancerColo-rectal CancerBrain TumorSolid Tumor, AdultPD1CTLA4
4SCAR-276NCT04432649I/IISolid Tumor
fhB7H3.CAR-TsNCT05211557I/IIOvarian Cancer
EGFR/B7H3 CAR-TNCT05341492Early Phase 1EGFR/B7H3-positive Advanced Lung/Breast Cancer
B7-H3 and 10 other CAR-TNCT03198052ILung Cancer
iC9-CAR.B7-H3 T cellsNCT06305299IOvary Neoplasm
Ovarian Cancer
Epithelial Ovarian Cancer
NCT06347068IBreast Cancer
Relapse
Resistant Cancer
4SCAR-T cellsNCT04637503I/IINeuroblastoma
CAR-γΓ TB7-H3-CAR -γΓ T cellsNCT06018363Brain Gliomas
CAR-gd TB7-H3-CAR -gd T cellsNCT05731219Relapsed/Refractory Acute Myeloid Leukemia
NCT05722171Relapsed/Refractory Acute Myeloid Leukemia
Radioimmunotherapy124I-omburtamabNCT01502917IBrain Cancer
Brain Stem Glioma
177Lu-DTPA-omburtamabNCT04167618I/IIMedulloblastoma, Childhood
NCT04315246I/IILeptomeningeal Metastasis
Solid Tumor, Adult
131I-omburtamabNCT00089245IBrain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
NCT00582608Not ApplicableCNS Cancer, Neuroblastoma, Sarcoma
NCT01099644IPeritoneal Cancer
NCT03275402II/IIINeuroblastoma, CNS Metastases, Leptomeningeal Metastases
NCT04022213IIDesmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma
NCT05064306Central Nervous, System/Leptomeningeal, Neoplasms
NCT04743661IIRecurrent Medulloblastoma
Recurrent Ependymoma
NCT05063357IDIPG
Anti-B7-H3 ADCC with Anti-PD-1 AbMGA271/pembrolizumab/MGA 012NCT02475213IMelanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urethelial Carcinoma
Enoblituzumab MGA012
MGD013
NCT04129320II/IIIHead and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
Anti-B7-H3 ADCC with Anti-PD-1 Ab or PD-1 X LAG-3 BiAbMGA271/MGA012/MGD013NCT04634825IIHead and neck cancer
Anti-B7-H3 ADC with Anti-PD-1 AbMGC018/MGA012NCT03729596I/II6 advanced solid tumors
B7-H3 CD3 BiAb with Anti-PD-1 AbMGD009/MGA012NCT03406949IAdvanced Solid Tumors
Anti-B7-H3 ADC with CD19 X CD3 BiAbMGC018/MGD019NCT05293496I7 advanced solid tumors
Anti-B7-H3 ADCC with NK cell enhancingMGA271/FT516 and IL2NCT04630769IOvarian Cancer, Fallopian Tube Adenocarcinoma, Primary Peritoneal Cavity Cancer
Anti-B7-H3 ADCC with Anti-CTLA-4 Abenoblituzumab plus ipilimumabNCT02381314IMelanoma, Non Small Cell Lung Cancer

Clinical Trials Targeting B7-H3.

4 Conclusion

Compared to other immune checkpoints, the uniqueness of B7-H3 lies in its ability to regulate both innate and adaptive immune responses. Furthermore, it promotes tumor development by stimulating various non-immune-related functions, making it anĀ important prognostic marker for adverse outcomes. B7-H3Ā influences the life processes of tumor cells, including apoptosis, proliferation, invasion, migration, drug resistance, resistanceĀ toĀ radiotherapy, metabolic processes, and abnormal angiogenesis, through the regulation of various signaling pathways. Therefore, inhibiting B7-H3 expression or blocking related signaling pathways may be an effective approach to prevent tumor progression.

Considering the high expression of B7-H3 in tumor cells and tumor vasculature, along with its low expression in normal vasculature, it becomes an ideal dual-target in cancer therapy. By considering B7-H3 as a bridge between tumor cells and the tumor vascular system, we can achieve dual therapeutic effects by targeting B7-H3. However, since the role and signaling pathways of B7-H3 may vary among different tumors and even within the vascular systems of different tumors, gaining a deeper understanding of the specific functions of B7-H3 in particular tumors will help us design more targeted treatment plans for patients, thus effectively controlling tumor development. This could be an important direction for future research in cancer therapy.

Statements

Author contributions

SW: Writing – original draft, Writing – review & editing. CH: Visualization, Writing – review & editing. KH: Visualization, Writing – review & editing. XJ: Conceptualization, Writing – review & editing.

Funding

The author(s) declare that no financial support was received for the research, authorship, and/or publication of this article.

Acknowledgments

The authors thank all members involved in this work.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

  • 1

    KontosFMichelakosTKurokawaTSadagopanASchwabJHFerroneCRet al. B7-H3: an attractive target for antibody-based immunotherapy. Clin Cancer Res. (2021) 27:1227–35. doi:Ā 10.1158/1078-0432.CCR-20-2584

  • 2

    KanchanRKDossDKhanPNasserMWMahapatraS. To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3. Biochim Biophys Acta (BBA) Rev Cancer. (2022) 1877:188783. doi:Ā 10.1016/j.bbcan.2022.188783

  • 3

    Flem-KarlsenKFodstadƘTanMNunes-XavierCE. B7-H3 in cancer – beyond immune regulation. Trends Cancer. (2018) 4:401–4. doi:Ā 10.1016/j.trecan.2018.03.010

  • 4

    SeamanSStevensJYangMYLogsdonDGraff-CherryCSt. CroixB. Genes that distinguish physiological and pathological angiogenesis. Cancer Cell. (2007) 11:539–54. doi:Ā 10.1016/j.ccr.2007.04.017

  • 5

    SeamanSZhuZSahaSZhangXMYangMYHiltonMBet al. Eradication of tumors through simultaneous ablation of CD276/B7-H3-positive tumor cells and tumor vasculature. Cancer Cell. (2017) 31:501–515.e8. doi:Ā 10.1016/j.ccell.2017.03.005

  • 6

    MortezaeeK. B7-H3 immunoregulatory roles in cancer. BioMed Pharmacother. (2023) 163:114890. doi:Ā 10.1016/j.biopha.2023.114890

  • 7

    FengYXieKYinYLiBPiCXuXet al. A novel anti-B7-H3 Ɨ Anti-CD3 bispecific antibody with potent antitumor activity. Life (Basel). (2022) 12:157. doi:Ā 10.3390/life12020157

  • 8

    SunMXieJZhangDChenCLinSChenYet al. B7-H3 inhibits apoptosis of gastric cancer cell by interacting with Fibronectin. J Cancer. (2021) 12:7518–26. doi:Ā 10.7150/jca.59263

  • 9

    ZhouXOuyangSLiJHuangXAiXZengYet al. The novel non-immunological role and underlying mechanisms of B7-H3 in tumorigenesis. J Cell Physiol. (2019) 234:21785–95. doi:Ā 10.1002/jcp.28936

  • 10

    ZhangQTangYHuGYuanZZhangSSunYet al. Comprehensive pan-cancer analysis identifies cellular senescence as a new therapeutic target for cancer: multi-omics analysis and single-cell sequencing validation. Am J Cancer Res. (2022) 12:4103–19.

  • 11

    SunJGuoYDLiXNZhangYQGuLWuPPet al. B7-H3 expression in breast cancer and upregulation of VEGF through gene silence. Onco Targets Ther. (2014) 7:1979–86. doi:Ā 10.2147/OTT

  • 12

    Montoyo-PujolYGGarcĆ­a-EscolanoMPonceJJDelgado-GarcĆ­aSMartĆ­nTABallesterHet al. Variable intrinsic expression of immunoregulatory biomarkers in breast cancer cell lines, mammospheres, and co-cultures. Int J Mol Sci. (2023) 24:4478. doi:Ā 10.3390/ijms24054478

  • 13

    ZhangTJiangBZouSTLiuFHuaD. Overexpression of B7-H3 augments anti-apoptosis of colorectal cancer cells by Jak2-STAT3. World J Gastroenterol. (2015) 21:1804–13. doi:Ā 10.3748/wjg.v21.i6.1804

  • 14

    WangRSunLXiaSWuHMaYZhanSet al. B7-H3 suppresses doxorubicin-induced senescence-like growth arrest in colorectal cancer through the AKT/TM4SF1/SIRT1 pathway. Cell Death Dis. (2021) 12:453. doi:Ā 10.1038/s41419-021-03736-2

  • 15

    HanSShiXLiuLZongLZhangJChenQet al. Roles of B7-H3 in cervical cancer and its prognostic value. J Cancer. (2018) 9:2612–24. doi:Ā 10.7150/jca.24959

  • 16

    LiuZZhangWPhillipsJBAroraRMcClellanSLiJet al. Immunoregulatory protein B7-H3 regulates cancer stem cell enrichment and drug resistance through MVP-mediated MEK activation. Oncogene. (2019) 38:88–102. doi:Ā 10.1038/s41388-018-0407-9

  • 17

    WangCLiYJiaLKimJKLiJDengPet al. CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. Cell Stem Cell. (2021) 28:1597–1613.e7. doi:Ā 10.1016/j.stem.2021.04.011

  • 18

    ZhangJLiuLHanSLiYQianQZhangQet al. B7-H3 is related to tumor progression in ovarian cancer. Oncol Rep. (2017) 38:2426–34. doi:Ā 10.3892/or.2017.5858

  • 19

    LiYYangXWuYZhaoKYeZZhuJet al. B7-H3 promotes gastric cancer cell migration and invasion. Oncotarget. (2017) 8:71725–35. doi:Ā 10.18632/oncotarget.v8i42

  • 20

    ZhongCTaoBChenYGuoZYangXPengLet al. B7-H3 regulates glioma growth and cell invasion through a JAK2/STAT3/slug-dependent signaling pathway. Onco Targets Ther. (2020) 13:2215–24. doi:Ā 10.2147/OTT

  • 21

    ZhaoJMengZXieCYangCLiuZWuSet al. B7-H3 is regulated by BRD4 and promotes TLR4 expression in pancreatic ductal adenocarcinoma. Int J Biochem Cell Biol. (2019) 108:84–91. doi:Ā 10.1016/j.biocel.2019.01.011

  • 22

    KangFBWangLJiaHCLiDLiHJZhangYGet al. B7-H3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via JAK2/STAT3/Slug signaling pathway. Cancer Cell Int. (2015) 15:45. doi:Ā 10.1186/s12935-015-0195-z

  • 23

    LiaoHDingMZhouNYangYChenL. B7āˆ’H3 promotes the epithelialāˆ’mesenchymal transition of NSCLC by targeting SIRT1 through the PI3K/AKT pathway. Mol Med Rep. (2022) 25:79. doi:Ā 10.3892/mmr

  • 24

    TekleCNygrenMKChenYWDybsjordINeslandJMMaelandsmoGMet al. B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes. Int J Cancer. (2012) 130:2282–90. doi:Ā 10.1002/ijc.26238

  • 25

    WangSZhangXNingHDongSWangGSunR. B7 homolog 3 induces lung metastasis of breast cancer through Raf/MEK/ERK axis. Breast Cancer Res Treat. (2022) 193:405–16. doi:Ā 10.1007/s10549-022-06520-8

  • 26

    XieJSunMZhangDChenCLinSZhangG. Fibronectin enhances tumor metastasis through B7-H3 in clear cell renal cell carcinoma. FEBS Open Bio. (2021) 11:2977–87. doi:Ā 10.1002/2211-5463.13280

  • 27

    LiuHTekleCChenYWKristianAZhaoYZhouMet al. B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation. Mol Cancer Ther. (2011) 10:960–71. doi:Ā 10.1158/1535-7163.MCT-11-0072

  • 28

    ZhaoXZhangGBGanWJXiongFLiZZhaoHet al. Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma. Oncol Lett. (2013) 5:805–12. doi:Ā 10.3892/ol.2013.1118

  • 29

    Flem-KarlsenKTekleCØyjordTFlørenesVAMælandsmoGMFodstadØet al. p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance. Sci Rep. (2019) 9:5839. doi: 10.1038/s41598-019-42303-w

  • 30

    ZhangPChenZNingKJinJHanX. Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells. Biochem Biophys Res Commun. (2017) 490:1132–8. doi:Ā 10.1016/j.bbrc.2017.07.001

  • 31

    MaYWangRLuHLiXZhangGFuFet al. B7-H3 promotes the cell cycle-mediated chemoresistance of colorectal cancer cells by regulating CDC25A. J Cancer. (2020) 11:2158–70. doi:Ā 10.7150/jca.37255

  • 32

    ZhouLZhaoY. B7-H3 induces ovarian cancer drugs resistance through an PI3K/AKT/BCL-2 signaling pathway. Cancer Manag Res. (2019) 11:10205–14. doi:Ā 10.2147/CMAR

  • 33

    YueGTangJZhangLNiuHLiHLuoS. CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma. J Gastrointest Oncol. (2021) 12:38–51. doi:Ā 10.21037/jgo

  • 34

    LimSLiuHMadeira da SilvaLAroraRLiuZPhillipsJBet al. Immunoregulatory protein B7-H3 reprograms glucose metabolism in cancer cells by ROS-mediated stabilization of HIF1α. Cancer Res. (2016) 76:2231–42. doi:Ā 10.1158/0008-5472.CAN-15-1538

  • 35

    LiZLiuJQueLTangX. The immunoregulatory protein B7-H3 promotes aerobic glycolysis in oral squamous carcinoma via PI3K/Akt/mTOR pathway. J Cancer. (2019) 10:5770–84. doi:Ā 10.7150/jca.29838

  • 36

    ShiTMaYCaoLZhanSXuYFuFet al. B7-H3 promotes aerobic glycolysis and chemoresistance in colorectal cancer cells by regulating HK2. Cell Death Dis. (2019) 10:308. doi:Ā 10.1038/s41419-019-1549-6

  • 37

    ZhuXShiYWangJ. B7-H3 regulates glucose metabolism in neuroblastom via stat3/c-met pathway. Appl Biochem Biotechnol. (2023) 196:1386–98. doi:Ā 10.1007/s12010-023-04606-7

  • 38

    PurvisIJAvilalaJGudaMRVenkataramanSVibhakarRTsungAJet al. Role of MYC-miR-29-B7-H3 in medulloblastoma growth and angiogenesis. J Clin Med. (2019) 8:1158. doi:Ā 10.3390/jcm8081158

  • 39

    WangRMaYZhanSZhangGCaoLZhangXet al. B7-H3 promotes colorectal cancer angiogenesis through activating the NF-ĪŗB pathway to induce VEGFA expression. Cell Death Dis. (2020) 11:55. doi:Ā 10.1038/s41419-020-2252-3

  • 40

    WuRZhangYXuXYouQYuCWangWet al. Exosomal B7-H3 facilitates colorectal cancer angiogenesis and metastasis through AKT1/mTOR/VEGFA pathway. Cell Signal. (2023) 109:110737. doi:Ā 10.1016/j.cellsig.2023.110737

  • 41

    ZhangXJiJZhangGFangCJiangFMaSet al. Expression and significance of B7-H3 and Tie-2 in the tumor vasculature of clear cell renal carcinoma. Onco Targets Ther. (2017) 0:5417–24. doi:Ā 10.2147/OTT

  • 42

    FanXHuangJHuBZhouJChenL. Tumor-expressed B7-H3 promotes vasculogenic mimicry formation rather than angiogenesis in non-small cell lung cancer. J Cancer Res Clin Oncol. (2023) 149:8729–41. doi:Ā 10.1007/s00432-023-04790-3

  • 43

    ChengRWangBCaiXRChenZSDuQZhouLYet al. CD276 promotes vasculogenic mimicry formation in hepatocellular carcinoma via the PI3K/AKT/MMPs pathway. Onco Targets Ther. (2020) 13:11485–98. doi:Ā 10.2147/OTT.S271891

  • 44

    HuXXuMHuYLiNZhouL. B7-H3, negatively regulated by miR-128, promotes colorectal cancer cell proliferation and migration. Cell Biochem Biophys. (2021) 79:397–405. doi:Ā 10.1007/s12013-021-00975-0

  • 45

    LiYZhangJHanSQianQChenQLiuLet al. B7-H3 promotes the proliferation, migration and invasiveness of cervical cancer cells and is an indicator of poor prognosis. Oncol Rep. (2017) 38:1043–50. doi:Ā 10.3892/or.2017.5730

  • 46

    TangXYLuoZLXiongYLYangJShiAPZhengKFet al. The proliferative role of immune checkpoints in tumors: double regulation. Cancers (Basel). (2022) 14:5374. doi:Ā 10.3390/cancers14215374

  • 47

    ShiYXuYXuZWangHZhangJWuYet al. TKI resistant-based prognostic immune related gene signature in LUAD, in which FSCN1 contributes to tumor progression. Cancer Lett. (2022) 532:215583. doi:Ā 10.1016/j.canlet.2022.215583

  • 48

    PulidoRNunes-XavierCE. Hopes on immunotherapy targeting B7-H3 in neuroblastoma. Transl Oncol. (2023) 27:101580. doi:Ā 10.1016/j.tranon.2022.101580

  • 49

    JiangBLiuFLiuZZhangTHuaD. B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway. Tumour Biol. (2016) 37:9465–72. doi:Ā 10.1007/s13277-015-4740-0

  • 50

    TanWQChenGYeMJiaB. Artemether regulates chemosensitivity to doxorubicin via regulation of B7-H3 in human neuroblastoma cells. Med Sci Monit. (2017) 23:4252–9. doi:Ā 10.12659/MSM.902068

  • 51

    WangSMouJCuiLWangXZhangZ. Astragaloside IV inhibits cell proliferation of colorectal cancer cell lines through down-regulation of B7-H3. BioMed Pharmacother. (2018) 102:1037–44. doi:Ā 10.1016/j.biopha.2018.03.127

  • 52

    WangXCYueXZhangRXLiuTYPanZZYangMJet al. Genome-wide RNAi screening identifies RFC4 as a factor that mediates radioresistance in colorectal cancer by facilitating nonhomologous end joining repair. Clin Cancer Res. (2019) 25:4567–79. doi:Ā 10.1158/1078-0432.CCR-18-3735

  • 53

    DeBerardinisRJLumJJHatzivassiliouGThompsonCB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. (2008) 7:11–20. doi:Ā 10.1016/j.cmet.2007.10.002

  • 54

    ZuoJWangBLongMGaoZZhangZWangHet al. The type 1 transmembrane glycoprotein B7-H3 interacts with the glycolytic enzyme ENO1 to promote Malignancy and glycolysis in HeLa cells. FEBS Lett. (2018) 592:2476–88. doi:Ā 10.1002/1873-3468.13164

  • 55

    LiuJYangSCaoBZhouGZhangFWangYet al. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. J Hematol Oncol. (2021) 14:21. doi:Ā 10.1186/s13045-020-01024-8

  • 56

    QiYChenDLuQYaoYJiC. Bioinformatic profiling identifies a fatty acid metabolism-related gene risk signature for Malignancy, prognosis, and immune phenotype of glioma. Dis Markers. (2019) 2019:3917040. doi:Ā 10.1155/2019/3917040

  • 57

    Al-OstootFHSalahSKhameesHAKhanumSA. Tumor angiogenesis: Current challenges and therapeutic opportunities. Cancer Treat Res Commun. (2021) 28:100422. doi:Ā 10.1016/j.ctarc.2021.100422

  • 58

    MichelakosTKontosFBarakatOMaggsLSchwabJHFerroneCRet al. B7-H3 targeted antibody-based immunotherapy of Malignant diseases. Expert Opin Biol Ther. (2021) 21:587–602. doi:Ā 10.1080/14712598.2021.1862791

  • 59

    de la CruzONHLópez-GonzÔlezJSGarcía-VÔzquezRSalinas-VeraYMMuñiz-LinoMAAguilar-CazaresDet al. Regulation networks driving vasculogenic mimicry in solid tumors. Front Oncol. (2020) 9:1419. doi: 10.3389/fonc.2019.01419

  • 60

    BaoRWangYLaiJZhuHZhaoYLiSet al. Enhancing anti-PD-1/PD-L1 immune checkpoint inhibitory cancer therapy by CD276-targeted photodynamic ablation of tumor cells and tumor vasculature. Mol Pharm. (2019) 16:339–48. doi:Ā 10.1021/acs.molpharmaceut.8b00997

  • 61

    ChenBZhengKFangSHuangKChuCZhuangJet al. B7H3 targeting gold nanocage pH-sensitive conjugates for precise and synergistic chemo-photothermal therapy against NSCLC. J Nanobiotechnol. (2023) 21:378. doi:Ā 10.1186/s12951-023-02078-9

  • 62

    KastenBBArendRCKatreAAKimHFanJFerroneSet al. B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models. Nucl Med Biol. (2017) 47:23–30. doi:Ā 10.1016/j.nucmedbio.2017.01.003

  • 63

    MaLLuoLQiaoHDongXPanSJiangHet al. Complete eradication of hepatocellular carcinomas by combined vasostatin gene therapy and B7H3-mediated immunotherapy. J Hepatol. (2007) 46:98–106. doi:Ā 10.1016/j.jhep.2006.07.031

  • 64

    ChengNBeiYSongYZhangWXuLZhangWet al. B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy. Biochem Pharmacol. (2021) 183:114298. doi:Ā 10.1016/j.bcp.2020.114298

Summary

Keywords

B7-H3, non-immune functions, tumor cells, tumor vasculature, cancer therapy

Citation

Wu S, Hu C, Hui K and Jiang X (2024) Non-immune functions of B7-H3: bridging tumor cells and the tumor vasculature. Front. Oncol. 14:1408051. doi: 10.3389/fonc.2024.1408051

Received

27 March 2024

Accepted

04 June 2024

Published

17 June 2024

Volume

14 - 2024

Edited by

Nitesh Kumar, National Institute of Pharmaceutical Education and Research, India

Reviewed by

Gautam Kumar, Sharda University, India

Sri Pragnya Cheruku, Manipal University, India

Updates

Copyright

*Correspondence: Xiaodong Jiang, ; Kaiyuan Hui,

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics